Answers are grounded in this paper and cite their sources.
ALBI grade appeared to be prognostic for outcomes with both atezolizumab + bevacizumab and sorafenib treatment in patients with HCC. Atezolizumab + bevacizumab preserved liver function for a numerically longer duration than sorafenib.
No takes yet. Share an insight, caveat, or question.
Kudo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: